Researchers find that repeated SNAC exposure altered gut bacteria and increased inflammatory markers in an animal study. While this does not show that SNAC directly causes harm, it highlights an ...

Blockbuster weight-loss drugs are transforming the way we treat obesity. But while costly injectable versions remain out of ...

Feb 4 (Reuters) - Novo Nordisk said on Wednesday it will launch some doses of its oral semaglutide for diabetes under the brand name Ozempic pill in the second quarter of this year. The company said ...

Hims & Hers is facing battles on multiple fronts as it seeks to maintain its lucrative business in copycat weight loss drugs.

Semaglutide, the active ingredient in the anti-obesity drug Wegovy, offers cardiovascular benefits for patients without diabetes who have established heart disease, but price reductions would be ...

Shanghai Shiling Pharmaceutical is aiming to complete global clinical trials by 2028 for an experimental weight-management ...

This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. Nausea is the most common side effect of semaglutide, the weight loss and diabetes medication sold under the brand names Ozempic and ...

A new study from Adelaide University is turning a spotlight on those tablet versions, finding that the absorption-enhancing ingredient salcaprozate sodium (SNAC) may have measurable adverse biological ...

The FDA has approved Wegovy (semaglutide) tablets, the first oral GLP-1 receptor agonist for the treatment of obesity.

The MarketWatch News Department was not involved in the creation of this content.-- Novo Nordisk's first big game spot introduces America to the FDA-approved Wegovy(R) pill -- the ...

Yes, Wegovy is available in a pill form. Originally, it was only available as a weekly injection, but the Food and Drug Administration (FDA) approved a daily tablet version in December 2025. The ...